bullish sentiment
Biotech

Why biotechs can benefit from the 'rational' IPO environment

2024 saw a healthier IPO market than 2023, with activity triggered by M&A that occurred in the back end of '23, Morgan Stanley's Chirag Surti said.
Gabrielle Masson Jan 24, 2025 10:30am
photo of a paraglider in the foreground with the alps in the background

Flagship vet plants CEO roots at Pharming—Chutes & Ladders

Jan 24, 2025 8:30am
Obesity drugs

Novo links next-gen obesity drug to 22% weight loss at Week 36

Jan 24, 2025 6:51am
finance numbers tape money

Obesity biotech Aardvark eyes IPO as Ascentage makes $126M debut

Jan 24, 2025 5:02am
woman in snow

AstraZeneca invests $570M to grow in Canada, adds 700 jobs

Jan 23, 2025 2:47pm
Intuitive Da Vinci 5

Intuitive plots full robot rollout while weighing tariff impacts

Jan 24, 2025 12:30pm
Medtech News

Roche nets clearances for point-of-care STI tests

Jan 23, 2025 12:00pm

Masimo lands new CEO from BD's patient monitoring division

Jan 23, 2025 10:30am

Artificial pancreas maker Beta Bionics sets IPO goal of $120M

Jan 22, 2025 11:20am

Abbott posts device sales gains after heart valve, CGM debuts

Jan 22, 2025 10:30am